Research programme: antibacterials - Meiji Seika Kaisha

Drug Profile

Research programme: antibacterials - Meiji Seika Kaisha

Alternative Names: CP-5484; CPZ-A; CPZ-B; CPZ-C; CPZ-D; CPZ-E; CPZ-F; CPZ-G; TS 2037

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Meiji Seika Pharma
  • Class Aminoglycosides; Carbapenems; Macrolides; Nucleosides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections
  • Discontinued Tuberculosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Japan
  • 24 Jul 2008 Preclinical development is ongoing
  • 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Viral Infections Antimicrobial Activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top